John Resnick

“When I hosted my first earnings call in February, I shared with you my initial impressions of Surtara, that we have an extraordinary business, one that is strategically critical to the future of drug development.”

“So, yes, it's been a couple of quarters. I joined in January. The changes that we've made to the go-to-market model really have come into effect in Q2 and beginning and have fully been rolled out in July, obviously, with the announcement of the new chief commercial officer today.”

“It's great to, it's great to be with you. So, you know, organizationally, we did announce some changes. It's been a pretty active first few months within Sertara.”

“It really only been five months. so I don't know if anything surprised me per se I think there are some areas where maybe I underestimated just how strong of a franchise it was I mean specifically around kind of scientific leadership you know the deep kind of regulatory expertise methodological leadership the…”

“Since we last spoke, I have crossed over the 100-day mark at Surtara, and I continue to be incredibly impressed by many things within the company.”